Belluti S, Imbriano C, Casarini L
Cancers (Basel). 2023; 15(18).
PMID: 37760622
PMC: 10526871.
DOI: 10.3390/cancers15184653.
Sabu A, J S, R G, E D
Bioinformation. 2023; 19(1):43-47.
PMID: 37720282
PMC: 10504496.
DOI: 10.6026/97320630019043.
Zhang Y, Pan H, Yu C, Liu R, Xing B, Jia B
Asian J Pharm Sci. 2023; 18(4):100827.
PMID: 37588993
PMC: 10425851.
DOI: 10.1016/j.ajps.2023.100827.
Fernandez-Garcia D, Nteliopoulos G, Hastings R, Rushton A, Page K, Allsopp R
Br J Cancer. 2022; 127(10):1858-1864.
PMID: 36088510
PMC: 9643413.
DOI: 10.1038/s41416-022-01962-9.
Karn V, Sandhya S, Hsu W, Parashar D, Singh H, Jha N
Cancer Cell Int. 2022; 22(1):234.
PMID: 35879772
PMC: 9316746.
DOI: 10.1186/s12935-022-02654-3.
CREBBP/EP300 acetyltransferase inhibition disrupts FOXA1-bound enhancers to inhibit the proliferation of ER+ breast cancer cells.
Bommi-Reddy A, Park-Chouinard S, Mayhew D, Terzo E, Hingway A, Steinbaugh M
PLoS One. 2022; 17(3):e0262378.
PMID: 35353838
PMC: 8967035.
DOI: 10.1371/journal.pone.0262378.
Relationship between serum lipid levels and the immune microenvironment in breast cancer patients: a retrospective study.
Goto W, Kashiwagi S, Kamei Y, Watanabe C, Aomatsu N, Ikeda K
BMC Cancer. 2022; 22(1):167.
PMID: 35164691
PMC: 8842971.
DOI: 10.1186/s12885-022-09234-8.
CBP/p300: Critical Co-Activators for Nuclear Steroid Hormone Receptors and Emerging Therapeutic Targets in Prostate and Breast Cancers.
Waddell A, Huang H, Liao D
Cancers (Basel). 2021; 13(12).
PMID: 34201346
PMC: 8229436.
DOI: 10.3390/cancers13122872.
Pharmacological Inhibition of CBP/p300 Blocks Estrogen Receptor Alpha (ERα) Function through Suppressing Enhancer H3K27 Acetylation in Luminal Breast Cancer.
Waddell A, Mahmud I, Ding H, Huo Z, Liao D
Cancers (Basel). 2021; 13(11).
PMID: 34199844
PMC: 8200112.
DOI: 10.3390/cancers13112799.
Comparison of two targeted ultra-deep sequencing technologies for analysis of plasma circulating tumour DNA in endocrine-therapy-resistant breast cancer patients.
Nteliopoulos G, Page K, Hills A, Howarth K, Emmett W, Green E
Breast Cancer Res Treat. 2021; 188(2):465-476.
PMID: 34097174
PMC: 8260509.
DOI: 10.1007/s10549-021-06220-9.
miR-200b restrains EMT and aggressiveness and regulates matrix composition depending on ER status and signaling in mammary cancer.
Piperigkou Z, Franchi M, Riethmuller C, Gotte M, Karamanos N
Matrix Biol Plus. 2021; 6-7:100024.
PMID: 33543022
PMC: 7852204.
DOI: 10.1016/j.mbplus.2020.100024.
Prognostic factors and survival outcomes according to tumor subtype in patients with breast cancer lung metastases.
Chen S, Yang J, Liu Y, You H, Dong Y, Lyu J
PeerJ. 2019; 7:e8298.
PMID: 31871847
PMC: 6924336.
DOI: 10.7717/peerj.8298.
mutations contribute to fulvestrant resistance in ER-positive breast cancer.
Huang D, Tang L, Yang F, Jin J, Guan X
Am J Transl Res. 2019; 11(9):6055-6065.
PMID: 31632573
PMC: 6789267.
Transactivation Function-1-Mediated Partial Agonist Activity of Selective Estrogen Receptor Modulator Requires Homo-Dimerization of the Estrogen Receptor α Ligand Binding Domain.
Arao Y, Korach K
Int J Mol Sci. 2019; 20(15).
PMID: 31366023
PMC: 6695978.
DOI: 10.3390/ijms20153718.
Role of SUMOylation in differential ERα transcriptional repression by tamoxifen and fulvestrant in breast cancer cells.
Traboulsi T, El Ezzy M, Dumeaux V, Audemard E, Mader S
Oncogene. 2018; 38(7):1019-1037.
PMID: 30190545
PMC: 6514857.
DOI: 10.1038/s41388-018-0468-9.
Enhancer mapping uncovers phenotypic heterogeneity and evolution in patients with luminal breast cancer.
Patten D, Corleone G, Gyorffy B, Perone Y, Slaven N, Barozzi I
Nat Med. 2018; 24(9):1469-1480.
PMID: 30038216
PMC: 6130800.
DOI: 10.1038/s41591-018-0091-x.
Good Guy or Bad Guy? The Duality of Wild-Type p53 in Hormone-Dependent Breast Cancer Origin, Treatment, and Recurrence.
McGowan E, Lin Y, Hatoum D
Cancers (Basel). 2018; 10(6).
PMID: 29857525
PMC: 6025368.
DOI: 10.3390/cancers10060172.
Reprogramming of the estrogen responsive transcriptome contributes to tamoxifen-dependent protection against tumorigenesis in the p53 null mammary epithelial cells.
Palaniappan M, Edwards D, Creighton C, Medina D, Conneely O
PLoS One. 2018; 13(3):e0194913.
PMID: 29590203
PMC: 5874056.
DOI: 10.1371/journal.pone.0194913.
Break Breast Cancer Addiction by CRISPR/Cas9 Genome Editing.
Yang H, Jaeger M, Walker A, Wei D, Leiker K, Weitao T
J Cancer. 2018; 9(2):219-231.
PMID: 29344267
PMC: 5771328.
DOI: 10.7150/jca.22554.
A review on current nanomaterials and their drug conjugate for targeted breast cancer treatment.
Lee J, Saiful Yazan L, Abdullah C
Int J Nanomedicine. 2017; 12:2373-2384.
PMID: 28392694
PMC: 5376210.
DOI: 10.2147/IJN.S127329.